Your browser doesn't support javascript.
loading
Antigenic cartography using hamster sera identifies SARS-CoV-2 JN.1 evasion seen in human XBB.1.5 booster sera.
Wang, Wei; Bhushan, Gitanjali L; Paz, Stephanie; Stauft, Charles B; Selvaraj, Prabhu; Goguet, Emilie; Bishop-Lilly, Kimberly A; Subramanian, Rahul; Vassell, Russell; Lusvarghi, Sabrina; Cong, Yu; Agan, Brian; Richard, Stephanie A; Epsi, Nusrat J; Fries, Anthony; Fung, Christian K; Conte, Matthew A; Holbrook, Michael R; Wang, Tony T; Burgess, Timothy H; Mitre, Edward; Pollett, Simon D; Katzelnick, Leah C; Weiss, Carol D.
Afiliação
  • Wang W; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Bhushan GL; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Paz S; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Stauft CB; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Selvaraj P; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Goguet E; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Bishop-Lilly KA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda, Maryland, USA.
  • Subramanian R; Biological Defense Research Directorate, Naval Medical Research Command, Fort Detrick, Maryland, USA.
  • Vassell R; Office of Data Science and Emerging Technologies, Office of Science Management and Operations, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Lusvarghi S; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Cong Y; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Agan B; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Ft. Detrick, Frederick, Maryland, USA.
  • Richard SA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda, Maryland, USA.
  • Epsi NJ; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Fries A; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda, Maryland, USA.
  • Fung CK; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Conte MA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Bethesda, Maryland, USA.
  • Holbrook MR; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
  • Wang TT; US Air Force School of Aerospace Medicine, Dayton, Ohio, USA.
  • Burgess TH; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Mitre E; Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
  • Pollett SD; Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Ft. Detrick, Frederick, Maryland, USA.
  • Katzelnick LC; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
  • Weiss CD; Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
bioRxiv ; 2024 Apr 06.
Article em En | MEDLINE | ID: mdl-38712124
ABSTRACT
Antigenic assessments of SARS-CoV-2 variants inform decisions to update COVID-19 vaccines. Primary infection sera are often used for assessments, but such sera are rare due to population immunity from SARS-CoV-2 infections and COVID-19 vaccinations. Here, we show that neutralization titers and breadth of matched human and hamster pre-Omicron variant primary infection sera correlate well and generate similar antigenic maps. The hamster antigenic map shows modest antigenic drift among XBB sub-lineage variants, with JN.1 and BA.4/BA.5 variants within the XBB cluster, but with five to six-fold antigenic differences between these variants and XBB.1.5. Compared to sera following only ancestral or bivalent COVID-19 vaccinations, or with post-vaccination infections, XBB.1.5 booster sera had the broadest neutralization against XBB sub-lineage variants, although a five-fold titer difference was still observed between JN.1 and XBB.1.5 variants. These findings suggest that antibody coverage of antigenically divergent JN.1 could be improved with a matched vaccine antigen.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article